Retatrutide in Australia: Regulatory Status, Clinical Research and What Consumers Should Know

Updated September 2026

Retatrutide is an investigational medicine currently being studied in clinical trials for obesity, overweight and associated metabolic conditions. It has generated significant interest because it acts on three hormonal pathways involved in energy regulation: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.

However, there is an important distinction between retatrutide being studied in clinical research and products marketed or sold to consumers as “retatrutide”.

As of September 2026, retatrutide has not been approved by the Therapeutic Goods Administration (TGA) for supply in Australia, and the TGA has issued specific warnings concerning products marketed as retatrutide. (Therapeutic Goods Administration, 2026a)

This article explains what retatrutide is, what the clinical research has reported so far, its current Australian regulatory position, and why consumers should be cautious about products claiming to contain it.

What is retatrutide?

Retatrutide, also known by the development code LY3437943, is an investigational molecule developed by Eli Lilly.

Unlike medicines that act primarily through one or two incretin-related pathways, retatrutide is designed to activate three receptors:

• GIP
• GLP-1
• glucagon

This combination is why retatrutide is commonly described in the scientific literature as a triple hormone receptor agonist. (Jastreboff et al., 2023)

The scientific rationale is that these pathways have different but interconnected roles in glucose regulation, appetite, energy balance and metabolism. Retatrutide is therefore being investigated to determine whether simultaneous activation of these pathways can produce clinically meaningful effects.

Importantly, being investigated through clinical trials does not mean that a medicine has been approved for general use.

Is retatrutide approved in Australia?

No.

As of September 2026, retatrutide has not been approved by the TGA and is not included in the Australian Register of Therapeutic Goods (ARTG) as an approved medicine.

The TGA’s September 2026 safety alert specifically states that retatrutide remains under clinical investigation and has not been approved by the TGA or any comparable international regulator. (Therapeutic Goods Administration, 2026a)

This distinction is important because the regulatory status of a medicine is separate from the amount of scientific research being conducted on it.

A medicine can have substantial clinical-trial evidence while still being an investigational, unapproved therapeutic good.

Therefore, Phase 3 research does not itself equal TGA approval.

What does the research say about retatrutide?

Retatrutide has progressed substantially through clinical development.

Early published studies provided evidence that the molecule could influence body weight and glycaemic measures. More recent Phase 3 research has expanded the investigation into larger populations and additional obesity-related conditions.

However, the strength and limitations of the evidence need to be considered separately from the medicine’s regulatory status.

Phase 2 research in obesity

One of the key early studies was published in the New England Journal of Medicine in 2023.

Jastreboff et al. conducted a randomised, double-blind, placebo-controlled Phase 2 trial involving adults with obesity or overweight with at least one weight-related condition.

Participants received different doses of retatrutide or placebo over 48 weeks.

The study reported dose-dependent reductions in body weight, with greater reductions observed at higher doses. Gastrointestinal adverse events were among the commonly reported adverse events, and increases in heart rate were also observed in a dose-related manner. (Jastreboff et al., 2023)

The study was important because it provided early clinical evidence supporting further investigation of the triple-receptor approach.

It was, however, a Phase 2 study, rather than evidence of regulatory approval.

Reference: Jastreboff et al. (2023), New England Journal of Medicine, 389, pp. 514–526. (New England Journal of Medicine)

Phase 2 research in type 2 diabetes

Retatrutide has also been investigated in adults with type 2 diabetes.

Rosenstock et al. published a randomised Phase 2 trial in The Lancet in 2023 involving adults with type 2 diabetes.

The study investigated different doses of retatrutide against placebo and dulaglutide. The researchers reported improvements in glycaemic measures and reductions in body weight across retatrutide treatment groups. Gastrointestinal adverse events were among the adverse events reported during the study. (Rosenstock et al., 2023)

The study provides clinical research evidence about retatrutide in type 2 diabetes, but again, clinical-trial findings should not be confused with regulatory approval.

Reference: Rosenstock et al. (2023), The Lancet, 402(10401), pp. 529–544. (PubMed)

What has happened with Phase 3 retatrutide research?

By 2026, retatrutide had progressed into a broad Phase 3 development program.

ClinicalTrials.gov records show Phase 3 studies investigating retatrutide in populations including people with obesity or overweight, with additional studies examining associated conditions. For example, TRIUMPH-1 investigated adults with obesity or overweight without type 2 diabetes, while other trials investigated populations including type 2 diabetes and cardiovascular disease. (ClinicalTrials.gov, 2026)

Eli Lilly announced topline Phase 3 results from several trials during 2026.

For example, the company reported results from:

• TRIUMPH-1, investigating adults with obesity or overweight and at least one weight-related condition without diabetes;
• TRIUMPH-2, investigating adults with obesity or overweight and type 2 diabetes; and
• TRIUMPH-3, investigating adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. (Eli Lilly and Company, 2026a; 2026b)

Eli Lilly reported substantial reductions in body weight in these studies, together with improvements in certain metabolic measures. These are company-reported topline results; detailed findings and subsequent regulatory assessment remain separate steps in the medicine-development process. (Eli Lilly and Company, 2026a; 2026b)

This is an important distinction when interpreting headlines about investigational medicines.

Phase 3 does not mean approved

A medicine can successfully complete clinical trials and still require regulatory review before it can be approved for general supply.

Regulatory authorities assess the evidence submitted by the medicine’s sponsor, including evidence relating to quality, safety and effectiveness.

Therefore, statements such as “Phase 3 proven”, “clinically approved” or “available as an approved medicine” should not be treated as interchangeable concepts.

As of September 2026, the TGA continues to identify retatrutide as an unapproved medicine. (Therapeutic Goods Administration, 2026a)

Why is the TGA concerned about products marketed as retatrutide?

The TGA has issued several warnings during 2026 concerning unapproved peptide products.

In June 2026, the TGA and Australia’s Chief Medical Officer warned about increasing availability, promotion and use of unapproved peptide products.

The statement noted that unapproved products are not evaluated by the TGA for safety, quality or effectiveness and specifically included retatrutide among examples of unapproved peptides. (Therapeutic Goods Administration, 2026b)

The TGA has also highlighted concerns about the contents, sterility, manufacturing conditions, labelling and concentration of unapproved peptide products. (Therapeutic Goods Administration, 2026c)

These concerns are particularly relevant when a product is marketed online using the name of an investigational medicine.

A September 2026 TGA safety alert involving a product sold as retatrutide

On 14 September 2026, the TGA published a specific safety alert concerning a product marketed as retatrutide.

According to the TGA, a consumer experienced uncontrollable vomiting that resulted in a torn oesophagus and hospital treatment after using the product.

The TGA subsequently obtained a sample of the product in its original unmarked vial and conducted laboratory testing.

The testing found that:

• the product contained no retatrutide;
• it contained undeclared semaglutide; and
• the amount of semaglutide detected was approximately eight times the level found in semaglutide products assessed by the TGA and included in the ARTG. (Therapeutic Goods Administration, 2026a)

This is an important example of why the name printed or used to market a peptide product cannot, by itself, establish what the product actually contains.

It also demonstrates the difference between investigational retatrutide being studied in controlled clinical research and an unapproved product being marketed outside that research environment.

Does a “research use only” label make retatrutide approved?

No.

A label or disclaimer describing a product as being for “research use only” does not, by itself, determine whether the product is regulated as a therapeutic good or whether it can legally be marketed for human use.

The TGA has warned about peptide products being promoted online despite being unapproved therapeutic goods. (Therapeutic Goods Administration, 2026c)

The regulatory classification of a product depends on factors including how the product is represented, promoted and supplied, rather than simply the wording printed on its packaging.

Can retatrutide be advertised in Australia?

This is an important distinction for consumers, businesses and publishers of health information.

The TGA regulates advertising of therapeutic goods, including unapproved therapeutic goods.

In July 2026, the TGA stated that advertising unapproved therapeutic goods to Australian consumers is generally unlawful. The TGA specifically identified websites, online marketplaces, social media, influencer content and other forms of digital marketing as relevant advertising channels. (Therapeutic Goods Administration, 2026d)

The TGA has also stated that its compliance activities include unlawful advertising and promotion of peptide products. (Therapeutic Goods Administration, 2026d)

This means that there is an important difference between:

For this reason, information about retatrutide should be presented carefully and factually, particularly when published on a commercial website.

What does “unapproved therapeutic good” mean?

An unapproved therapeutic good is a therapeutic good that has not been included in the ARTG for the relevant purpose.

The TGA explains that unapproved peptide products have not undergone the TGA’s assessment for safety, quality and effectiveness. (Therapeutic Goods Administration, 2026b; 2026c)

This does not necessarily mean that every individual molecule has no scientific evidence behind it.

Instead, it means that the particular product has not received the relevant Australian regulatory approval for general supply.

That distinction is particularly important with investigational medicines such as retatrutide.

Why online “retatrutide” products are difficult to assess

Consumers may encounter products online described as:

• retatrutide;
• LY3437943;
• research peptides;
• laboratory peptides; or
• “research use only” products.

However, a product description does not establish its identity, purity, concentration, sterility or manufacturing quality.

The TGA has reported concerns about unapproved peptide products being supplied in poorly labelled or unmarked vials, making it difficult to establish exactly what they contain. (Therapeutic Goods Administration, 2026c)

The September 2026 retatrutide safety alert provides a particularly clear illustration: a product marketed as retatrutide was laboratory tested by the TGA and found to contain no retatrutide at all, but instead undeclared semaglutide at a substantially higher concentration than assessed Australian semaglutide products. (Therapeutic Goods Administration, 2026a)

Retatrutide: research status versus Australian regulatory status

The simplest way to understand the current position is to separate the scientific and regulatory questions.

(Jastreboff et al., 2023; Rosenstock et al., 2023; Therapeutic Goods Administration, 2026a; ClinicalTrials.gov, 2026)

What should consumers understand about retatrutide in Australia?

The most important point is that retatrutide remains an investigational medicine rather than an approved medicine for general supply in Australia.

There is legitimate scientific interest in retatrutide, and the clinical development program has progressed considerably since the first Phase 2 studies were published.

At the same time, the existence of clinical research does not mean that every product sold under the name “retatrutide” contains the investigational molecule or meets the quality and safety standards applied to approved medicines.

The TGA’s September 2026 laboratory findings demonstrate why this distinction matters. (Therapeutic Goods Administration, 2026a)

For consumers reading information about retatrutide online, it is therefore useful to ask three separate questions:

1. What does the published clinical research actually show?
2. What is the current regulatory status in Australia?
3. What evidence exists that a particular product actually contains what its label claims?

Those questions are not interchangeable.

Final thoughts

Retatrutide is one of the more closely studied investigational medicines in the emerging field of multi-receptor metabolic therapies.

Published Phase 2 research has provided evidence of effects on body weight and glycaemic measures, while Phase 3 research has expanded investigation into larger and more diverse populations. (Jastreboff et al., 2023; Rosenstock et al., 2023)

However, research progress and regulatory approval are separate processes.

As of September 2026, retatrutide has not been approved by the TGA. The TGA has also issued specific warnings about unapproved products marketed as retatrutide, including a September 2026 laboratory investigation in which a product sold as retatrutide was found to contain undeclared semaglutide rather than retatrutide. (Therapeutic Goods Administration, 2026a)

For this reason, reliable information about retatrutide should distinguish clearly between published clinical research, regulatory status and products marketed outside approved regulatory pathways.

Information current to September 2026. Regulatory status and clinical-trial findings may change as further evidence becomes available.

References

Clinical research

• Jastreboff, A.M. et al. (2023) ‘Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial’, New England Journal of Medicine, 389, pp. 514–526. View the NEJM publication
• Rosenstock, J. et al. (2023) ‘Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA’, The Lancet, 402(10401), pp. 529–544. View the PubMed record

Australian regulatory information

• Therapeutic Goods Administration (2026a) TGA tests counterfeit retatrutide product following serious adverse event report, 14 September 2026. TGA safety alert: retatrutide product
• Therapeutic Goods Administration (2026b) Concerns regarding the public health risks associated with unapproved peptide products, 19 June 2026. TGA statement on unapproved peptide products
• Therapeutic Goods Administration (2026c) Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. TGA guidance on unapproved peptide products
• Therapeutic Goods Administration (2026d) Unapproved peptide product promoters and suppliers are put on notice, 20 July 2026. TGA information on advertising unapproved peptide products

Clinical trial information

• ClinicalTrials.gov (2026) TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight, NCT05929066. View the ClinicalTrials.gov record
• Eli Lilly and Company (2026a) Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial, 21 May 2026. View the Eli Lilly press release
• Eli Lilly and Company (2026b) Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, 23 July 2026. View the Eli Lilly press release

Related reading

• Approved vs Unapproved Therapeutic Goods: What Is the Difference?
• What Is a Schedule 4 Medicine in Australia?
• What Is the ARTG? Understanding Australia’s Register of Therapeutic Goods